[1] Le Berre CHonap SPeyrin-Biroulet L. Ulcerative
colitis[J]. The Lancet, 2023, 402 (10401): 571-584.
[2] Gros BKaplan G G. Ulcerative Colitis in Adults: A
Review[J]. Jama, 2023, 330 (10): 951-965.
[3] Chiba MTsuji TNakane Ket al. High Remission Rate
with Infliximab and Plant-Based Diet as First-Line (IPF)
Therapy for Severe Ulcerative Colitis: Single-Group Trial[J].
The Permanente journal, 2020, 24 : 1-10.
[4] Oliver AChase A BWeihe Cet al. High-Fiber, WholeFood Dietary Intervention Alters the Human Gut Microbiome
but Not Fecal Short-Chain Fatty Acids[J]. mSystems, 2021, 6
(2).
[5] Zhao HZhou YXu Jet al. Short-chain fatty acidproducing bacterial strains attenuate experimental ulcerative
colitis by promoting M2 macrophage polarization via JAK/
STAT3/FOXO3 axis inactivation[J]. Journal of translational
medicine, 2024, 22 (1): 369.
[6] Liu QJian WWang Let al. Alleviation of DSS-induced colitis in mice by a new-isolated Lactobacillus
acidophilus C4[J]. Front Microbiol, 2023, 14 : 1137701.
[7] Kim W KMin S GKwon Het al. Lactobacillus
rhamnosus KBL2290 Ameliorates Gut Inflammation in a
Mouse Model of Dextran Sulfate Sodium-Induced Colitis[J].
Journal of microbiology (Seoul, Korea), 2023, 61 (7): 673-
682.
[8] Dai WZhang JChen Let al. Discovery of Bacteroides
uniformis F18-22 as a Safe and Novel Probiotic Bacterium
for the Treatment of Ulcerative Colitis from the Healthy
Human Colon[J]. Int J Mol Sci, 2023, 24 (19).
[9] Ye ZTan QWoltemate Set al. Escherichia coli Nissle
Improves Short-Chain Fatty Acid Absorption and Barrier
Function in a Mouse Model for Chronic Inflammatory
Diarrhea[J]. Inflamm Bowel Dis, 2024, : .
[10] Kruis WFric PPokrotnieks Jet al. Maintaining
remission of ulcerative colitis with the probiotic Escherichia
coli Nissle 1917 is as effective as with standard mesalazine[J].
Gut, 2004, 53 (11): 1617-23.
[11] [Expert consensus on the clinical application of
bifidobacterium tetravaccine tablets for digestive diseases][J].
Zhonghua nei ke za zhi, 2024, 63 (10): 927-960.
[12] Zhou SZhu WQin Xet al. Synthesis and Evaluation
of Antioxidant and Potential Prebiotic Activities of Acetylated
and Butyrylated Fructo-Oligosaccharides[J]. Antioxidants,
2022, 11 (9).
[13] Lunken G RTsai KSchick Aet al. Prebiotic
Enriched Exclusive Enteral Nutrition Suppresses Colitis
via Gut Microbiome Modulation and Expansion of Antiinflammatory T Cells in a Mouse Model of Colitis[J]. Cellular
and molecular gastroenterology and hepatology, 2021, 12 (4):
1251-1266.
[14] Li ZLi ZZhu Let al. Effects of Xylo-Oligosaccharide
on the Gut Microbiota of Patients With Ulcerative Colitis in
Clinical Remission[J]. Frontiers in nutrition, 2021, 8 : 778542.
[15] Ryan J JMonteagudo-Mera AContractor Net al.
Impact of 2'-Fucosyllactose on Gut Microbiota Composition
in Adults with Chronic Gastrointestinal Conditions: Batch
Culture Fermentation Model and Pilot Clinical Trial
Findings[J]. Nutrients, 2021, 13 (3).
[16] Wilson BEyice ÖKoumoutsos Iet al. Prebiotic
Galactooligosaccharide Supplementation in Adults with
Ulcerative Colitis: Exploring the Impact on Peripheral Blood
Gene Expression, Gut Microbiota, and Clinical Symptoms[J].
Nutrients, 2021, 13 (10).
[17] Huang XHu JZhang Het al. Clostridium butyricum
and Chitooligosaccharides in Synbiotic Combination
Ameliorate Symptoms in a DSS-Induced Ulcerative Colitis
Mouse Model by Modulating Gut Microbiota and Enhancing
Intestinal Barrier Function[J]. Microbiol Spectr, 2023, 11 (2):
e0437022.
[18] Sharma SBhatia RDevi Ket al. A synbiotic
combination of Bifidobacterium longum Bif10 and
Bifidobacterium breve Bif11, isomaltooligosaccharides and
finger millet arabinoxylan prevents dextran sodium sulphate
induced ulcerative colitis in mice[J]. Int J Biol Macromol,
2023, 231 : 123326.
[19] Zhou SWang MLi Wet al. Comparative efficacy and
tolerability of probiotic, prebiotic, and synbiotic formulations
for adult patients with mild-moderate ulcerative colitis in
an adjunctive therapy: A network meta-analysis[J]. Clinical
Nutrition, 2024, 43 (1): 20-30.
[20] Liu CQi XLi Det al. Limosilactobacillus fermentum
HF06-derived paraprobiotic and postbiotic alleviate intestinal
barrier damage and gut microbiota disruption in mice with
ulcerative colitis [J]. Journal of the science of food and
agriculture, 2024, 104 (3): 1702-1712.
[21] Xue LZhao YWang Het al. The effects of live
and pasteurized Akkermansia muciniphila on DSS-induced
ulcerative colitis, gut microbiota, and metabolomics in
mice[J]. Food & Function, 2023, 14 (10): 4632-4646.
[22] Bu LLi YWang Cet al. Preventive effect of
Lacticaseibacillus rhamnosus 2016SWU.05.0601 and its
postbiotic elements on dextran sodium sulfate-induced colitis
in mice[J]. Front Microbiol, 2024, 15 : 1342705.
[23] Caldeira L FBorba H HTonin F Set al. Fecal
microbiota transplantation in inflammatory bowel disease
patients: A systematic review and meta-analysis[J]. PLoS
One, 2020, 15 (9): e0238910.
[24] Bethlehem LEstevinho M MGrinspan Aet al.
Microbiota therapeutics for inflammatory bowel disease: the
way forward[J]. The lancet. Gastroenterology & hepatology,
2024, 9 (5): 476-486.
[25] Lopetuso L RDeleu SGodny Let al. The first
international Rome consensus conference on gut microbiota
and faecal microbiota transplantation in inflammatory boweldisease[J]. Gut, 2023, 72 (9): 1642-1650.
[26] Lima S FGogokhia LViladomiu Met al. Transferable
Immunoglobulin A–Coated Odoribacter splanchnicus in
Responders to Fecal Microbiota Transplantation for Ulcerative
Colitis Limits Colonic Inflammation[J]. Gastroenterology,
2022, 162 (1): 166-178.
[27] Yao WXu ZSun Jet al. Deoxycholic acidfunctionalised nanoparticles for oral delivery of rhein[J].
European journal of pharmaceutical sciences : official journal
of the European Federation for Pharmaceutical Sciences,
2021, 159 : 105713.
[28] Heidari HBagherniya MMajeed Met al. Curcuminpiperine co-supplementation and human health: A
comprehensive review of preclinical and clinical studies[J].
Phytotherapy research : PTR, 2023, 37 (4): 1462-1487.